ArticleCardiovascular therapeutics2025
CXCL1 Promotes Fibrotic Remodeling in Atrial Fibrillation via Activation of TXNDC5 and Endoplasmic Reticulum Stress.
Article in Cardiovascular therapeutics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Atrial fibrosis is a key structural substrate in atrial fibrillation (AF). This work was conducted to investigate the profibrotic effects of chemokine C-X-C motif Ligand 1 (CXCL1) and elucidate the actions of endoplasmic reticulum stress (ERS) and ER-resident protein thioredoxin domain-containing Protein 5 (TXNDC5) in this process. Methods: Serum CXCL1 concentrations were measured in patients with AF and healthy controls. The effects of CXCL1 on atrial fibrosis were evaluated using ex vivo rat atrial tissue culture. Additionally, the influence of CXCL1 on collagen synthesis, ERS activation, and TXNDC5 expression was assessed in primary rat cardiac fibroblasts. Pharmacological inhibition of ERS and gene silencing of TXNDC5 were employed to decipher underlying mechanisms. Results: CXCL1 levels were elevated in patients with AF compared to controls. In ex vivo rat atrial tissue, CXCL1 treatment induced marked fibrosis and upregulated the expression of ERS markers GRP78 and ATF6, as well as TXNDC5. In cardiac fibroblasts, CXCL1 promoted the secretion of Collagen I, Collagen III, and TGF- Conclusion: CXCL1 promotes atrial fibrosis through the activation of ERS and upregulation of TXNDC5, potentially contributing to atrial remodeling and the pathogenesis of AF. Targeting the CXCL1-ERS-TXNDC5 axis may offer a novel therapeutic approach for preventing and treating AF-related atrial fibrosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.